PE20191251A1 - Moleculas de fijacion para el tratamiento del cancer - Google Patents

Moleculas de fijacion para el tratamiento del cancer

Info

Publication number
PE20191251A1
PE20191251A1 PE2019001228A PE2019001228A PE20191251A1 PE 20191251 A1 PE20191251 A1 PE 20191251A1 PE 2019001228 A PE2019001228 A PE 2019001228A PE 2019001228 A PE2019001228 A PE 2019001228A PE 20191251 A1 PE20191251 A1 PE 20191251A1
Authority
PE
Peru
Prior art keywords
cancer
treatment
molecules
fixation
cdh17
Prior art date
Application number
PE2019001228A
Other languages
English (en)
Spanish (es)
Inventor
Klaus-Peter Kuenkele
Ertan Eryilmaz
Timothy Fenn
Rajkumar Ganesan
Juan Manuel Garcia-Martinez
Jason Ho
Christian Koessl
Saurabh Sen
Abdulsalam Shaaban
Vladimir Voynov
Andreas Wernitznig
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20191251A1 publication Critical patent/PE20191251A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE2019001228A 2016-12-22 2017-12-21 Moleculas de fijacion para el tratamiento del cancer PE20191251A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437770P 2016-12-22 2016-12-22
EP17155973.5A EP3360898A1 (en) 2017-02-14 2017-02-14 Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer

Publications (1)

Publication Number Publication Date
PE20191251A1 true PE20191251A1 (es) 2019-09-18

Family

ID=58043942

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001228A PE20191251A1 (es) 2016-12-22 2017-12-21 Moleculas de fijacion para el tratamiento del cancer

Country Status (15)

Country Link
US (2) US10858438B2 (ko)
EP (2) EP3360898A1 (ko)
JP (1) JP7196076B2 (ko)
KR (1) KR102651761B1 (ko)
CN (1) CN110582513B (ko)
AU (1) AU2017384687A1 (ko)
BR (1) BR112019011750A2 (ko)
CA (1) CA3046591A1 (ko)
CO (1) CO2019006320A2 (ko)
EA (1) EA201991480A1 (ko)
MA (1) MA47121A (ko)
MX (1) MX2019007511A (ko)
PE (1) PE20191251A1 (ko)
TW (1) TWI790219B (ko)
WO (1) WO2018115231A2 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
EP3725370A1 (en) * 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
AU2021276332A1 (en) * 2020-05-19 2022-11-17 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
JP2024503508A (ja) 2021-01-15 2024-01-25 シージェン インコーポレイテッド 免疫調節性抗体－薬物コンジュゲート
AR124812A1 (es) 2021-02-03 2023-05-10 Seagen Inc Conjugados y compuestos inmunoestimulantes
CN117813120A (zh) * 2021-06-07 2024-04-02 旗舰先锋创新Vii有限责任公司 用于靶向递送治疗剂的组合物和方法
CN113512117B (zh) * 2021-07-12 2023-08-22 武汉麦考津生物科技有限公司 一种可结合cd206的抗体及其应用
WO2023015169A1 (en) * 2021-08-02 2023-02-09 Tavotek Biotech (Suzhou) Ltd Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
EP4388013A1 (en) * 2021-08-20 2024-06-26 University of Virginia Patent Foundation Strategy for highly superior dr5 activation including in tumors and cancers
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
US20240052065A1 (en) 2022-07-15 2024-02-15 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
WO2024081930A1 (en) * 2022-10-14 2024-04-18 Flagship Pioneering Innovations Vii, Llc Compositions and methods for targeted delivery of therapeutic agents
CN115785269B (zh) * 2022-11-01 2023-09-22 四川大学 抗pd-l1的抗体及其应用
WO2024102962A1 (en) * 2022-11-10 2024-05-16 Immuvia Inc Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731A (en) 1848-08-22 Elisha k
US168A (en) 1837-04-17 Improvement in fire-arms
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
ES2108460T3 (es) 1993-06-03 1997-12-16 Therapeutic Antibodies Inc Fragmentos de anticuerpos en terapeutica.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
CA2433877C (en) 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
NZ532881A (en) 2001-12-20 2008-04-30 Human Genome Sciences Inc Antibodies that immunospecifically bind to trail receptors
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
CA2534898A1 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060228352A1 (en) 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
EP1945671A2 (en) 2005-10-12 2008-07-23 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
AP2011005984A0 (en) 2009-04-20 2011-12-31 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17.
AU2010303142B2 (en) 2009-09-29 2013-05-09 Roche Glycart Ag Bispecific death receptor agonistic antibodies
AU2011318574B2 (en) * 2010-10-20 2016-03-03 Oxford Biotherapeutics Ltd. Antibodies
US20130025987A1 (en) 2011-07-18 2013-01-31 David Batterbee Methods and apparatus for controlling a fluid damper
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
NO2776305T3 (ko) 2014-04-23 2018-01-27
CN106659790A (zh) 2014-08-12 2017-05-10 诺华股份有限公司 抗cdh6抗体药物缀合物
KR20170084202A (ko) 2014-11-14 2017-07-19 노파르티스 아게 항체 약물 접합체
DK3247728T3 (da) 2015-01-20 2020-07-13 Igm Biosciences Inc Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
JP6602875B2 (ja) 2015-01-26 2019-11-06 マクロジェニクス，インコーポレーテッド Ｄｒ５結合ドメインを含む多価分子
EP3848393A1 (en) 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Antibody molecules for cancer treatment
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer

Also Published As

Publication number Publication date
CN110582513A (zh) 2019-12-17
JP7196076B2 (ja) 2022-12-26
TWI790219B (zh) 2023-01-21
KR102651761B1 (ko) 2024-03-26
WO2018115231A3 (en) 2018-08-02
MA47121A (fr) 2019-10-30
CN110582513B (zh) 2023-11-14
KR20190099223A (ko) 2019-08-26
US10858438B2 (en) 2020-12-08
TW201835102A (zh) 2018-10-01
EA201991480A1 (ru) 2020-01-15
MX2019007511A (es) 2019-09-04
WO2018115231A2 (en) 2018-06-28
EP3360898A1 (en) 2018-08-15
US20180179287A1 (en) 2018-06-28
US20210095038A1 (en) 2021-04-01
CA3046591A1 (en) 2018-06-28
US11851495B2 (en) 2023-12-26
EP3559040A2 (en) 2019-10-30
BR112019011750A2 (pt) 2019-10-29
JP2020501586A (ja) 2020-01-23
CO2019006320A2 (es) 2019-06-28
AU2017384687A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
PE20191251A1 (es) Moleculas de fijacion para el tratamiento del cancer
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
CL2014002257A1 (es) Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2017002405A1 (es) Compuestos bicíclicos fusionados, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades o desordenes relacionados con el fxr.
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
MX2017009608A (es) Compuestos anticancerigenos.
MX370519B (es) Sulfonamidas con sustitucion biarilo y su uso.
CO2018005354A2 (es) Derivados novedosos de diamino piridina
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
AR110568A1 (es) Moléculas de fijación para el tratamiento del cáncer
CL2019001684A1 (es) Moléculas de fijación para el tratamiento del cáncer.
SV2016005282A (es) Nuevos compuestos
BR112017012931A2 (pt) métodos para redução de agregação plaquetária e tratamento de doença cardiovascular e outros distúrbios médicos
BR112016028017A2 (pt) Inibidor de quinase alk e método de preparação e usos do mesmo